Ms. Carolyn Bonner reports

MEDICUS PHARMA LTD. ANNOUNCES THE FILING OF A FINAL BASE SHELF PROSPECTUS

Medicus Pharma Ltd. has filed a final short-form base shelf prospectus with the securities regulatory authorities in each of the provinces and territories of Canada. The shelf prospectus allows Medicus to offer, from time to time over a 25-month period, up to $50-million (or the equivalent in other currencies) of common shares, preferred shares, warrants, subscription receipts, debt securities and units comprising more than one of the foregoing securities, or any combination thereof, in all of the provinces and territories of Canada.

The company has filed the shelf prospectus to maintain financial flexibility but has no immediate plans to undertake an offering of securities under the shelf prospectus. There is no certainty that any securities will be offered or sold under the shelf prospectus within the 25-month effective period. Should Medicus decide to offer any securities during the 25-month effective period, the specific terms will be set forth in a prospectus supplement to the shelf prospectus.

A copy of the shelf prospectus may be found on SEDAR+.

About Medicus Pharma Ltd.

Medicus Pharma is a clinical-stage multistrategy holding company focused on investing in and accelerating novel life sciences and biotechnology companies through FDA (Food and Drug Administration) approved clinical trials.

Through its diverse experience and extensive industry network, Medicus is building a leading pharmaceutical holding company, committed to delivering better treatment outcomes, and alleviate pain and suffering. Utilizing a thesis-driven collaborative process, Medicus identifies, acquires and advances relatively derisked clinical-stage assets through clinical development and commercialization.

Skinject Inc., a wholly owned subsidiary of Medicus Pharma, is a development-stage life sciences company focused on commercializing novel, non-invasive treatment for basal cell and squamous cell skin cancer using patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumour cells. The company currently has an FDA approved phase 2 trial actively recruiting patients.

We seek Safe Harbor.